Stimulating Angiogenesis to Prevent Ischemic Retinopathy

Ophthalmology

Volumn 116, Issue 9, 2009, Pages 1597-1598

  Sears, Jonathan E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; DISEASE COURSE; EDITORIAL; HUMAN; LASER SURGERY; PATHOGENESIS; PRIORITY JOURNAL; RETINA DETACHMENT; RETROLENTAL FIBROPLASIA; UNITED STATES; VITRECTOMY;

ERYTHROPOIETIN; HUMANS; INFANT, NEWBORN; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 69249170235     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.04.024     Document Type: Editorial

References (15)

1. Terry T.L. Fibroblastic overgrowth of persistent tunica vasculosa lentis in infants born prematurely: II. Report of cases-clinical aspects. Trans Am Ophthalmol Soc 40 (1942) 262-284
2. Patz A., Hoeck L.E., and De La Cruz E. Studies on the effect of high oxygen administration in retrolental fibroplasia. I. Nursery observations. Am J Ophthalmol 35 (1952) 1248-1253
3. Ashton N., Ward B., and Serpell G. Role of oxygen in the genesis of retrolental fibroplasia: a preliminary report. Br J Ophthalmol 37 (1953) 513-520
4. Kinsey V.E. Retrolental fibroplasia; cooperative study of retrolental fibroplasia and the use of oxygen. AMA Arch Ophthalmol 56 (1956) 481-543
5. Phelps D.L. Retinopathy of prematurity. Pediatr Rev 16 (1995) 50-56
6. Chow L.C., Wright K.W., and Sola A. Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants?. Pediatrics 111 (2003) 339-345
7. Good W.V. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 102 (2004) 233-248 discussion 248-50
8. Capone Jr. A., and Trese M.T. Lens-sparing vitreous surgery for tractional stage 4A retinopathy of prematurity retinal detachments. Ophthalmology 108 (2001) 2068-2070
9. Aiello L.P. Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res 29 (1997) 354-362
10. Sato T., Kusaka S., Shimojo H., et al. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology 116 (2009) 1599-1603
11. Chen J., Connor K.M., Aderman C.M., and Smith L.E. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest 118 (2008) 526-533
12. Semenza G.L., Nejfelt M.K., Chi S.M., and Antonarakis S.E. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc Natl Acad Sci U S A 88 (1991) 5680-5684
13. Sears J.E., Hoppe G., Ebrahem Q., and Anand-Apte B. Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy. Proc Natl Acad Sci U S A 105 (2008) 19898-19903
14. Morita M., Ohneda O., Yamashita T., et al. HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J 22 (2003) 1134-1146
15. Kaelin Jr. W.G., and Ratcliffe P.J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30 (2008) 393-402